A novel, new molecular entity in clinical development for the treatment of multiple CNS disorders.Read more
Follow-on agents and alternative formulations, including the ITI-007 long-acting injectable.Read more
PDE Inhibitor Platform
Leader in PDE1 inhibitor development with first in-human studies completed.Read more
Drug Discovery Platform
State-of-the-art drug discovery efforts complemented by CNSProfile™, our novel, proprietary platform based on Nobel Prize-winning science.Read more
The safety and efficacy of these investigational agents have not been established.